InMed Pharmaceuticals Inc. (INM)
NASDAQ: INM · Real-Time Price · USD
0.884
-0.036 (-3.95%)
Mar 9, 2026, 1:17 PM EDT - Market open
InMed Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Revenue | 4.51 | 4.94 | 4.6 | 4.14 | 1.09 | - | Upgrade
|
| Revenue Growth (YoY) | -6.73% | 7.50% | 11.18% | 279.61% | - | - | Upgrade
|
| Cost of Revenue | 3.17 | 3.24 | 3.5 | 2.73 | 0.55 | - | Upgrade
|
| Gross Profit | 1.34 | 1.71 | 1.1 | 1.4 | 0.54 | - | Upgrade
|
| Selling, General & Admin | 6.5 | 6.56 | 5.8 | 5.85 | 6.67 | 4.48 | Upgrade
|
| Research & Development | 2.47 | 2.85 | 3.22 | 3.73 | 7.28 | 5.34 | Upgrade
|
| Operating Expenses | 9.18 | 9.62 | 9.24 | 9.78 | 14.14 | 9.94 | Upgrade
|
| Operating Income | -7.84 | -7.92 | -8.13 | -8.38 | -13.59 | -9.94 | Upgrade
|
| Interest Expense | -0.02 | -0.37 | - | - | - | - | Upgrade
|
| Interest & Investment Income | 0.24 | 0.16 | 0.53 | 0.49 | 0.1 | 0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.04 | -0.03 | -0.06 | -0.05 | -0.12 | -0.16 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | - | -0.12 | Upgrade
|
| EBT Excluding Unusual Items | -7.66 | -8.16 | -7.67 | -7.93 | -13.61 | -10.2 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -0.2 | - | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -2.02 | - | Upgrade
|
| Asset Writedown | - | - | - | - | -1.45 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -1.31 | - | Upgrade
|
| Pretax Income | -7.66 | -8.16 | -7.67 | -7.93 | -18.6 | -10.2 | Upgrade
|
| Income Tax Expense | - | - | 0.01 | 0.01 | - | - | Upgrade
|
| Net Income | -7.66 | -8.16 | -7.68 | -7.95 | -18.6 | -10.2 | Upgrade
|
| Net Income to Common | -7.66 | -8.16 | -7.68 | -7.95 | -18.6 | -10.2 | Upgrade
|
| Shares Outstanding (Basic) | 3 | 1 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 3 | 1 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 359.88% | 156.13% | 211.26% | 336.59% | 108.64% | 28.72% | Upgrade
|
| EPS (Basic) | -2.92 | -8.36 | -20.14 | -64.92 | -663.32 | -759.16 | Upgrade
|
| EPS (Diluted) | -2.92 | -8.36 | -20.14 | -64.92 | -663.32 | -759.16 | Upgrade
|
| Free Cash Flow | -7.42 | -7.77 | -7 | -7.45 | -15.62 | -9.79 | Upgrade
|
| Free Cash Flow Per Share | -2.83 | -7.96 | -18.36 | -60.81 | -557.14 | -728.60 | Upgrade
|
| Gross Margin | 29.73% | 34.53% | 23.95% | 33.93% | 49.89% | - | Upgrade
|
| Operating Margin | -174.01% | -160.20% | -176.92% | -202.60% | -1247.60% | - | Upgrade
|
| Profit Margin | -170.07% | -165.14% | -166.94% | -192.18% | -1707.32% | - | Upgrade
|
| Free Cash Flow Margin | -164.69% | -157.14% | -152.14% | -180.02% | -1434.03% | - | Upgrade
|
| EBITDA | -7.63 | -7.71 | -7.91 | -8.18 | -13.41 | -9.82 | Upgrade
|
| EBITDA Margin | -169.32% | -155.89% | -172.15% | -197.71% | - | - | Upgrade
|
| D&A For EBITDA | 0.21 | 0.21 | 0.22 | 0.2 | 0.19 | 0.12 | Upgrade
|
| EBIT | -7.84 | -7.92 | -8.13 | -8.38 | -13.59 | -9.94 | Upgrade
|
| EBIT Margin | -174.01% | -160.20% | -176.92% | -202.60% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.